Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/40300
Title: Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study
Authors: Suryavanshi, Nishi
Murrill, Matthew
Gupta, Amita
Hughes, Michael
Hesseling, Anneke
Kim, Soyeon
Naini, Linda
Jones, Lynne
Smith, Betsy
Gupte, Nikhil
Dawson, Rodney
Mave, Vidya
Meshram, Sushant
Mendoza-Ticona, Alberto
Sanchez, Jorge
Kumarasamy, Nagalingeswaran
Comins, Kyla
Conradie, Francesca
Shenje, Justin
Nerette Fontain, Sandy
Garcia-Prats, Anthony
Asmelash, Aida
Nedsuwan, Supalert
Mohapi, Lerato
Lalloo, Umesh
Cristina Garcia Ferreira, Ana
Okeyo, Elisha
Swindells, Susan
Churchyard, Gavin
Shah, N Sarita
Affilliation: Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Pune, India.
Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Pune, India./ Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Desmond Tutu TB Centre, Stellenbosch University, Tygerberg, South Africa.
Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Social and Scientific Systems, Inc, Silver Springs, Maryland.
Frontier Science and Technology Research Foundation, Amherst, New York.
National Institutes of Health, Bethesda, Maryland.
Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Pune, India./ Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
University of Cape Town Lung Institute, Mowbray, South Africa.
Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Pune, India./ Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Byramjee Jeejeebhoy Government Medical College Clinical Trials Unit, Pune, India.
Barranco Clinical Research Site.
Asociación Civil Impacta Salud y Educación, San Miguel Clinical Research Site, Lima, Peru.
Chennai Antiviral Research and Treatment Clinical Research Site, India.
TASK Applied Science Clinical Research Site, Bellville.
University of the Witwatersrand Helen Joseph Hospital, Johannesburg.
South African Tuberculosis Vaccine Initiative, Cape Town, South Africa.
GHESKIO Centers-Institute of Infectious Diseases and Reproductive Health, Port-au-Prince, Haiti.
Desmond Tutu TB Centre, Stellenbosch University, Tygerberg, South Africa.
Gaborone Clinical Research Site, Botswana.
Program for HIV Prevention and Treatment-Chiangrai Prachanukroh Hospital, Thailand.
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg.
Durban International Clinical Research Site, South Africa.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Kenya Medical Research Institute, Kisumu.
University of Nebraska Medical Center, Omaha.
Aurum Institute./ School of Public Health, University of the Witwatersrand, Johannesburg./ Advancing Care and Treatment for TB/HIV, South African Medical Research Council, Parktown, South Africa.
Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract: Background. Household contacts (HHCs) of individuals with multidrug-resistant tuberculosis (MDR-TB) are at high risk of infection and subsequent disease. There is limited evidence on the willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of TB disease. Methods. In this cross-sectional study of HHCs of MDR-TB and rifampicin-resistant tuberculosis (RR-TB) index cases from 16 clinical research sites in 8 countries, enrollees were interviewed to assess willingness to take a hypothetical, newly developed MDR TPT if offered. To identify factors associated with willingness to take MDR TPT, a marginal logistic model was fitted using generalized estimating equations to account for household-level clustering. Results. From 278 MDR-TB/RR-TB index case households, 743 HHCs were enrolled; the median age of HHCs was 33 (interquartile range, 22–49) years, and 62% were women. HHC willingness to take hypothetical MDR TPT was high (79%) and remained high even with the potential for mild side effects (70%). Increased willingness was significantly associated with current employment or schooling (adjusted odds ratio [aOR], 1.83 [95% confidence interval {CI}, 1.07–3.13]), appropriate TB-related knowledge (aOR, 2.22 [95% CI, 1.23–3.99]), confidence in taking MDR TPT (aOR, 7.16 [95% CI, 3.33–15.42]), and being comfortable telling others about taking MDR TPT (aOR, 2.29 [95% CI, 1.29–4.06]). Conclusions. The high percentage of HHCs of MDR-TB/RR-TB index cases willing to take hypothetical MDR TPT provides important evidence for the potential uptake of effective MDR TPT when implemented. Identified HHC-level variables associated with willingness may inform education and counseling efforts to increase HHC confidence in and uptake of MDR TPT.
Keywords: Contacts
Drug resistance
Preventive therapy
Prophylaxis
Tuberculosis
Issue Date: 2020
Publisher: Oxford
Citation: SURYAVANSHI, Nishi et al. Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study. Clinical Infectious Diseases, v. 70, n. 3, p. 436-445, 2020.
DOI: 10.1093/cid/ciz254
ISSN: 1058-4838
Copyright: restricted access
Appears in Collections:INI - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Willingness_Ana_Ferreira_INI_Lapclin-AIDS_2020.pdf1.56 MBAdobe PDF    Request a copy



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.